NeurologyLive® Friday 5 — October 27, 2023

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 27, 2023.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Special Episode: FDA Approves Zilucoplan for Myasthenia Gravis

James F. “Chip” Howard, MD, Distinguished Professor of Neuromuscular Disease and professor of neurology and medicine at The University of North Carolina at Chapel Hill School of Medicine, and the lead global investigator of the phase 3 RAISE study (NCT04115293), discussed the downstream effects of this approval for myasthenia gravis, the available data from clinical studies, and the advantages for patients and physicians.

Special Episode: FDA Approves Zilucoplan for Myasthenia Gravis

2: The Pharmacist Perspective on MS Biosimilars and the Possible Monitoring Needs

Alicyn Magruder, PharmD, BCACP, MSCS, offers insight into the pharmacist's role in patient education on biosimilars for MS, and the group discusses the potential need for a long-term monitoring system. [WATCH TIME: 10 minutes]

The Pharmacist Perspective on MS Biosimilars and the Possible Monitoring Needs

3: NeuroVoices: Barry Singer, MD, on Recent Strides in the Treatment and Management of Multiple Sclerosis

The director and founder of The MS Center for Innovations in Care provided perspective on some of the significant strides made in recent years to improve the care and access to affordable treatments for patients with multiple sclerosis.

NeuroVoices: Barry Singer, MD, on Recent Strides in the Treatment and Management of Multiple Sclerosis

4: Achieving Consensus and Expanding Treatment Horizons in NMOSD: Lorna Galleguillos, MD; Ricardo Alonso MD, MSc

The neuroimmunologist at Clínica Alemana de Santiago and the head of the University Center for Multiple Sclerosis at Ramos Mejía Hospital talked about Latin America’s pursuit of expanding treatment options and patient inclusivity as a focus of neurological censuses in NMOSD. [WATCH TIME: 5 minutes]

Achieving Consensus and Expanding Treatment Horizons in NMOSD: Lorna Galleguillos, MD; Ricardo Alonso MD, MSc

5: Mechanistic Potential of Pepinemab, a SEMA4D-Blocking Antibody: Terrence L. Fisher, PhD

The senior vice president of clinical development at Vaccinex provided commentary on a presentation from CTAD 2023 highlighting the therapeutic potential of peptinemab, an agent that’s shown success in Huntington disease, in patients with Alzheimer disease. [WATCH TIME: 3 minutes]

 Mechanistic Potential of Pepinemab, a SEMA4D-Blocking Antibody: Terrence L. Fisher, PhD
Related Videos
Shahid Nimjee, MD, PhD
Peter J. McAllister, MD, FAAN
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
Michael Levy, MD, PhD
Michael Levy, MD, PhD
Michael Kaplitt, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.